南國置業(002305.SZ)擬設立南國置業資產支持專項計劃
格隆匯4月22日丨南國置業(002305.SZ)公佈,為繼續盤活存量資產和拓寬融資渠道,公司擬聘請符合要求的金融機構及中介機構作為項目的參與方,在南國置業自持物業範圍中選擇符合交易所掛牌要求的標的資產,設立“南國置業資產支持專項計劃(CMBS)”(具體銷售機構和管理人以發行時最終確定的主體為準,專項計劃名稱以最終獲批的名稱為準),進行資產證券化融資。此次專項計劃擬發行規模不超過人民幣20億元。融資期限不超過18年,每3年開放回售贖回。
此次專項計劃將設置優先級資產支持證券和次級資產支持證券。專項計劃成立後,優先級資產支持證券將在證券交易所掛牌交易。次級資產支持證券由公司及指定主體持有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.